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Abstract  SA Fam Pract 2009;51(6):492-495
Prevention of mother-to-child transmission (PMTCT) is a major intervention world-wide in the fight against the HIV pandemic, and has resulted in 
markedly reduced rates of mother-to-child transmission rates in well-resourced countries.
However, it seems that barriers to implementation of the programme exist at all levels of health care at all facilities providing maternal care.
Aim: To conduct a clinical audit of the PMTCT programme at a regional hospital in Pietermaritzburg, KwaZulu-Natal, South Africa.
Methods: Data was collected from an analysis of antenatal and medical records of women who attended antenatal care and delivered at the regional 
hospital between January and December 2007. Only pregnant women who attended antenatal care at this regional hospital and delivered in its 
facilities were selected for the study. Patients eligible for review were identified using the labour ward delivery log book.
Results: Of the 499 records analysed, 479 women (96%) were offered testing, of which 473 accepted. Of those tested, 227 (48%) were HIV positive. 
Only 15 (6.1%) of the 246 who tested negative were re-tested. CD4 counts were done for only 159 (70%) of the 227 HIV-positive women. More 
importantly, only 134 (84.3%) received their results.
Of the 227 HIV-positive women, only 131 (57.7%) were given 200 mg nevirapine at ≥ 28 weeks gestation (to take home and swallow once they had 
strong labour pains); 185 (81.5%) took nevirapine before delivery (i.e. the total number of both those that took NVP < 2hrs and > 2hrs) 143 (77.3%) 
took nevirapine > 2 hours before delivery and 84 (37%) took nevirapine < 2 hours before delivery. Of the babies, 208 (91.6%) were given nevirapine 
within 72 hours.
Discussion: This audit shows that progress has been made in the implementation of PMTCT of HIV at this regional hospital by the high uptake of HIV 
testing; however, barriers to full implementation are caused by the lack of integration of testing, counselling and obtaining CD4 count results.
 Peer reviewed. (Submitted:2008-11-13, Accepted:2009-02-06). © SAAFP 
Introduction
Prevention of mother-to-child transmission (PMTC) is a major intervention 
world-wide in the fight against the HIV pandemic and has resulted in 
markedly reduced rates of mother-to-child transmission (MTCT) in well-
resourced countries. However, progress in resource-limited countries 
has been slow.1
A key barrier to a successful PMTCT programme is lack of knowledge of 
HIV serostatus. It is therefore not surprising that in 2000, WHO/UNAIDS 
recommended that voluntary counselling and HIV testing coupled with 
antiretroviral therapy for all HIV-positive pregnant women and their 
children be made available as a minimum standard package of care.2
The principles of these recommendations have not changed although 
modifications have been made over time. The major steps in these 
guidelines are summarised by Pattinson et al3 and are similar to 
suggestions made by Bolu et al.4 According to these, the key factors 
contributing to the scale-up of testing and counselling include a 
policy of provider-initiated testing and counselling with right to refuse 
(opt-out), group pre-test counselling, rapid HIV testing, innovative staffing 
strategies, and community and male involvement. These authors also 
state that integration of testing, counselling within the community, and 
all maternal and child health settings are critical for successful PMTCT 
programmes.
The researchers’ impression is that there are barriers in each of these 
steps in their environment at a regional hospital in KwaZulu-Natal. They 
therefore decided to conduct a clinical audit of the PMTCT programme 
at this health facility. 
Setting 
This regional hospital has 900 beds, approximately 7 500 pregnant 
women deliver each year, and approximately 750 pregnant women 
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receive antenatal care annually. Most women who deliver at this regional 
hospital receive their antenatal care at community clinics.
In South Africa, prior to March 2007, the National Department of Health 
policy for the standard PMTCT programme consisted of provider-initiated 
counselling and testing, staging, and provision of single dose nevirapine 
for PMTCT or HAART (highly active antiretroviral therapy) for maternal 
health. The policy also included standard antenatal care and counselling 
on infant feeding choices, management during labour and postnatal follow 
up of mothers and neonates. In March 2007, the National Department of 
Health approved the implementation of dual therapy instead of single 
dose NVP in all its health facilities. Dual therapy for PMTCT included 
a short course of zidovudine (AZT) 300 mg 12-hourly from 28 weeks 
gestation and 300 mg three-hourly during labour, boosted by a single 
dose of NVP 200 mg. Babies receive a single dose of NVP 2 mg/kg 
plus AZT 12 mg 12-hourly for seven days.5 Dual therapy consisting of 
nevirapine and zidovudine was only introduced at the regional hospital 
under study in October 2007.
Pre- and post-test counselling is done by trained lay counsellors who 
document the numbers of those tested, those who obtain their results, 
and those who want to be tested but who do not want to know their 
results. All information is documented in registers. There are no patient 
identifiers but a “share barcode” is used.5 
The routine tests for HIV testing include two rapid tests of different brands. 
If both tests are positive, the patient is regarded as positive. If there is 
a discrepancy in the results, an ELISA is done as a confirmatory test. All 
mothers, irrespective of their HIV status, receive post-test counselling and 
advice on safe sexual practices. Mothers who test negative are advised 
to retest in three months. In addition, all HIV-positive mothers are given 
a single 200 mg dose of NVP to take home and are informed to take 
the tablet when they experience strong and regular labour contractions. 
Confirmation that the woman has taken NVP is done on admission to the 
labour ward and the baby is given a dose (2 mg/kg of NVP syrup) within 
72 hours of birth. 
Mothers who are HIV positive and have a CD
4 count below 200 cells/µl 
or stage IV disease are referred to the antiretroviral clinics to undergo 
adherence training, further counselling, nutritional advice, supportive 
therapy and antiretroviral drugs according to the National Guidelines.5
Data collection
Following institutional Biomedical Research Ethics approval, data was 
collected by review of medical records of pregnant women who attended 
antenatal care and delivered at the hospital between January 2007 and 
December 2007. Only pregnant women who attended antenatal care 
at this regional hospital and delivered in its facilities were selected for 
the study while those who did not attend antenatal care at the regional 
hospital, but delivered at the hospital were excluded.
Patients eligible for the review were identified using labour ward delivery 
logbooks.
Each record was evaluated for evidence of voluntary counselling and 
testing (VCT), availability of results, whether CD
4 count for HIV-positive 
women was performed, screening for syphilis, whether re-testing 
for HIV after three months was offered to women who initially tested 
negative, referral and initiation of antiretroviral therapy, administration of 
nevirapine (NVP) to the mother in labour and to the baby in the immediate 
post-delivery period, and information on the choice of infant feeding.
The data were recorded on a structured form and no patient identifiers 
were used. 
Statistical analysis/Sample size 
Simple statistics were utilised and all results were presented as 
frequencies, means, range, percentages and standard deviations. 
Sample size was not estimated as this was a clinical audit.   
Results
Between January 2007 and December 2007, 750 pregnant women 
attended this regional hospital for antenatal care and delivery. The 
medical records of 499 of these patients were identified and used for 
data collection and analysis. The remainder were not available due to 
poor filing at the medical records office.
The mean age was 26 years and the age group 20 to 28 years made up 
53.5% of the total sample size. As indicated in Figure 1, 479 (96%) were 
offered testing, of which 473 (98.7%) accepted. Of those tested, 227 
(48%) were HIV positive. Of the 246 who tested negative, only 15 (6.1%) 
were retested and all 15 were negative. Additionally, 464 were tested for 
syphilis and 14 (3%) were seropositive. 
Table I shows that CD4 counts were done for only 159 (70%) of the 227 
HIV-positive women, and 134 (84.3%) of those received their results. 
Thirty-five had CD4 counts < 200 cells/μL, of which 21 (60%) were 
initiated on HAART.
Table II shows that 60 (44.8%) received their results in less than 14 days. 
There was no documentation on whether the remainder had CD4 tests 
done or had obtained results. 
Table III shows that of the 227 HIV-positive women, only 131 (57.7%) 
were given 200 mg tablets of NVP at 28 weeks gestation or more to 
take home and drink at the onset of labour. Out of the total of 227, 185 
(81.5%) women took NVP before delivery, 29 (22.1%) took their NVP 
at home at the onset of labour, while 156 (78.8%) took the NVP at the 
hospital. Only 143 (63%) took NVP more than two hours before delivery 
while 84 (37%) took NVP less than two hours before delivery. With regard 
to neonates, 208 (91.6%) of the babies were given NVP at the correct 
time (within 72 hours of delivery).
Regarding infant feeding, 179 (78.9%) of the 227 HIV-positive mothers 
chose to formula feed their babies. Only 428 (85.8%) medical charts 
had proper documentation on the mode of delivery, while 71 (14.2%) 
charts either had no documentation or the delivery page was missing. Of 
these 428 women, 207 (48.4%) were HIV-positive. Of these, 138 (66.7%) 
women delivered by normal vaginal delivery and the remainder (n = 69; 
33.3%) had either emergency or elective caesarean sections. (Elective 
Caesarean section for HIV-positive women is not standard practice in 
the public sector.) 
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Discussion
The comprehensive PMTCT service recommended by the National 
Department of Health includes investigation for HIV infection, staging 
of the disease and initiation of HAART and prophylaxis for opportunistic 
infections if indicated.5 This audit showed that a large proportion of 
pregnant women (479; 96%) who received antenatal care at the regional 
hospital audited, were offered HIV counselling and voluntary testing. 
Moreover, 472 (99.8%) were counselled for HIV testing and tested at 
the first antenatal visit. The uptake of HIV testing during pregnancy 
was very high (98.7%), above the 70% reported by Barron et al.6 These 
authors, however, obtained their data from the district health information 
system and their findings reflect the national trend of data two or more 
years earlier than the audit presented here. The current data reflects 
an improvement over a short time period. Similar findings have been 
reported from Malawi. Manzi et al1 found that 9 out of 10 mothers 
accepted VCT, and approximately a quarter tested HIV positive. 
The three-month retesting guideline for those who initially tested negative 
was very low (n = 15; 6.1%), even though about 81.3% of the women 
delivered after more than three months after the initial test was done. 
This low rate of retesting is of grave concern as there is an increased 
risk for MTCT of HIV during the acute phase of infection when viral loads 
are very high. This group poses the highest risk of MTCT transmission. 
Obviously more attention should be paid to this aspect by retraining 
counsellors and integrating the programme into routine antenatal care, 
so that doctors, midwives and nurses take ownership of the care of HIV 
positive patients during pregnancy, labour and the post-delivery period. 
Previous studies have shown a detection rate of 6% in those who are 
retested in geographical areas with high HIV incidence rates.7 
Of particular concern is the testing for CD4 counts and obtaining those 
results. The review of records showed that 159 (70%) HIV-positive 
mothers had their blood specimens taken for CD
4 counts and, although 
134 received their results before discharge from hospital, only 60 
received their results within two weeks of the test. The reasons for 
this delay include the fact that patients booked late or did not keep 
appointments at the HIV clinic. In the majority of the cases, however, 
the attending medical staff did not record the CD
4 count or check for the 
results. This resulted in failure to provide integrated comprehensive care 
during the antenatal, intrapartum and postpartum periods. 
750 had antenatal care
499 medical records analysed
134 (84.3%) received 
results
35 (24%) < 200 cells/μl
21 of the 35 (60%) initiated on 
HAART in pregnancy
479 (96%) offered VCT 20 (4%) not offered
473 (98.7%) accepted testing 6 (1.3%) declined
227 (48%) HIV+ 246 (52%) HIV-
159 (70%) CD4 done
68 (30%) CD4 not 
done
15 (6.1%) retested 
472 (99.7%) same day rapid 
test results
1 (0.2%) had an ELISA on the 
same day
Figure 1: Flow diagram of results
Table I: CD4 counts and initiation of HAART in HIV-positive pregnant 
women
CD4 count done (n = 227) 159 (70%)
CD4 count results received (n = 159) 134 (84.3%)
CD4 count ≤ 200 (n = 134) 35 (26.1%)
HAART initiated during pregnancy (n = 35) 21 (60%)
Table II: Time taken to obtain CD4 count results and reasons for delay
n = 134
Time taken to obtain CD4 results:
•  ≤14 days
•  > 4 days but ≤ 1 month





•  Delay in booking for antenatal care 
•  Appointments not kept by patients 
•  No record of CD4 count or results recorded 




Table III: NVP given for PMTCT (n = 227)
NVP given for PMTCT at 28 weeks (n = 227) 131 (57.7%)
NVP taken before delivery (n = 227) 185 (81.5%)
NVP taken at home at the onset of labour (n = 131) 29 (22.1%)
NVP taken at the hospital (n = 198) 156 (78.8%)
NVP taken > 2 hours before delivery (n = 227) 143 (63%)
NVP given to the baby within 72 hours of delivery (n = 227) 208 (91.6%)
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Of the 35 women whose CD4 count was < 200 cells/µl, only 21 (60%) 
were initiated on HAART. The reasons identified for this low rate included 
the following: delay in or absence of obtaining CD
4 results, delayed 
referral to the ARV clinic, long waiting times for counselling on adherence 
to the HAART drug regimen, and the fact that some women who were 
34 weeks gestation and more did not meet the guidelines for HAART. 
It should be recognised that guidelines are not rules – they should 
allow flexibility, particularly for pregnant women, who should have an 
accelerated process if they require HAART. This again shows the lack 
of integration of the PMTCT programme into antenatal care. Doctors 
and midwives probably perceive the PMTCT programme as being 
separate from routine antenatal care, creating obstacles for the proper 
management of HIV-positive women.
There was not enough documentation to comment on postnatal care and 
follow-up. The researchers’ impression was that postnatal care is poor in 
all health facilities in KwaZulu-Natal and needs to be improved.
Conclusions
The uptake of HIV testing in this audit was surprisingly high and indicates 
significant progress in the implementation of a PMTCT programme in this 
regional hospital. The findings of delay in obtaining CD
4 counts in HIV-
positive women and in the initiation of HAART in pregnancy suggest that 
there are barriers to the integration of the PMTCT programme into routine 
antenatal care, These barriers in service delivery probably include the 
fact that health professionals may consider the PMTCT as a stand-alone 
programme and therefore do not adhere to guidelines, resulting in poor 
continuum of care and poor documentation during pregnancy, delivery 
and the puerperium. All of these factors lead to missed opportunities in 
the prevention of MTCT of HIV.
Recommendations
Areas that need further improvement include: (i) retesting after three 
months for pregnant HIV-negative women; (ii) proper counselling on the 
need to take AZT from 28 weeks and NVP at the onset of labour; (iii) 
obtaining blood for specimens for CD
4 counts at the time the patient 
tests positive for HIV and early assessment of the result; (iv) removal 
of bottlenecks that interfere with early commencement of HAART 
for pregnant women who need it for their own health; and (v) proper 
documentation by medical staff to facilitate evaluations of the PMTCT.
These goals may be achieved by continued in-service training of all 
medical staff on PMTCT and specifically by integrating the programme 
into routine antenatal care.
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